Clinical Trial: A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer

U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07822373) titled 'A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer' on Sept. 10.

Brief Summary: The purpose of this study is to evaluate whether Enfortumab Vedotin in combination with Pembrolizumab can achieve a clinical response that preserves the bladder and avoids the need for cystectomy or radiation therapy in patients with urothelial cancer.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Muscle-invasive Bladder Urothelial Carcinoma

Intervention: DRUG: Enfortumab vedotin

Enfortumab vedotin 1.25 mg/kg, IV on days 1 and 8 on a 21...